Leukemia Clinical Trials

Showing 2961-2980 of 10,987 trials

Tolerance of Extensive Hydrolyzed Whey Protein Milk Among Infant With Mild to Moderate CMPA

NCT06204770

The goal of this clinical trial is to evaluate the tolerance, safety and efficacy of Nutribaby Royal Pepti Junior (NR Pepti) among infants with mild to moderate Cow's Milk Protein Allergy (CMPA). The main questions it aims to answer are: 1. Is NR Pepti tolerable among infants with mild to moderate CMPA? 2. Is NR Pepti safe and effective among infants with mild to moderate CMPA? Participants will be asked to use NR Pepti as part their management of mild to moderate CMPA

Mild to Moderate Cows' Milk Protein Allergy

Danone Specialized Nutrition Indonesia15 participantsStarted Jul 2023

Tangerang, Banten, Indonesia • Tangerang, Banten, Indonesia • Jakarta, DKI Jakarta, Indonesia +2 more locations

RECRUITINGNA

Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors

NCT06107608

Evaluation of the relation between baseline fibroblast activation protein (FAP) expression based on Ga-FAPI uptake with patient outcome among NSCLC patients receiving immunotherapy for recurrent/metastatic disease.

Non Small Cell Lung Cancer

Jules Bordet Institute58 participantsStarted Jun 2023

Brussels, Belgium

Enrolling By InvitationPhase 2

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

NCT06901622

To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma

Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

The First Affiliated Hospital of Zhengzhou University50 participantsStarted Nov 2024

Zhengzhou, China

Tolerance of Extensive Hydrolyzed Whey Protein Milk Among Infant With Mild to Moderate CMPA

Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Related Searches

Effects Branch PA Stenting d-TGA, ToF and TA

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response

Study About Contrast Media

Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children

Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer

Gut Health in Children With Cancer

Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

Metatarsophalangeal Arthrodesis of the Hallux

Plyometry and Tapping in the Functional Improvement of Non-professional Basketball Players

STI Prophylaxis and Emergence of Antimicrobial Resistance

Chronic Lung Allograft Dysfunction MRI Study

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease